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Abstract
Calcyclin-binding protein (CacyBP/SIP), identified on the basis of its ability to interact with S100 proteins in a calcium-
dependent manner, was previously found to inhibit the proliferation and tumorigenesis of gastric cancer cells in our
laboratory. Importantly, the effects of S100 proteins on the biological behavior of CacyBP/SIP in gastric cancer remain
unclear. Herein, we report the construction of eukaryotic expression vectors for wild-type CacyBP/SIP and a truncated
mutant lacking the S100 protein binding domain (CacyBP/SIPDS100). The expressions of the wild-type and truncated
recombinant proteins were demonstrated by transfection of MKN45 gastric cancer cells. Co-immunoprecipitation assays
demonstrated interaction between S100A6 and wild-type CacyBP/SIP in MKN45 cells. Removal of the S100 protein binding
domain dramatically reduced the affinity of CacyBP/SIP for S100 proteins as indicated by reduced co-immunoprecipitation
of S100A6 by CacyBP/SIPDS100. The MTT assay, FACS assay, clonogenic assay and tumor xenograft experiment were
performed to assess the effect of CacyBP/SIP on cell growth and tumorigenesis in vitro and in vivo. Overexpression of
CacyBP/SIP inhibited the proliferation and tumorigenesis of MKN45 gastric cancer cells; the proliferation and tumorigenesis
rates were even further reduced by the expression of CacyBP/SIPDS100. We also showed that S100 proteins negatively
regulate CacyBP/SIP-mediated inhibition of gastric cancer cell proliferation, through an effect on b-catenin protein
expression and transcriptional activation of Tcf/LEF. Although the underlying mechanism of action requires further
investigation, this study provides new insight into the interaction between S100 proteins and CacyBP/SIP, which might
enrich our knowledge of S100 proteins and be helpful for our understanding of the development of gastric cancer.
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Introduction
S100 proteins are the largest subgroup within the EF-hand
Ca
2+-binding protein family and are characterized by their cell-
and tissue-specific expression patterns. These proteins are known
to regulate intracellular processes such as the cell cycle transition
and cellular growth, differentiation and motility [1]. A unique
feature of these proteins is that individual members are localized in
specific cellular compartments from which some are able to
relocate upon Ca
2+ activation [2,3]. Upon translocation, these
proteins may transduce the Ca
2+ signal in a temporal and spatial
manner by interacting with different S100 protein-specific targets.
Interestingly, most S100 genes are located in a gene cluster on
human chromosome 1q21, a site of frequent chromosomal
abnormalities [4]. This association suggests a link between
chromosomal abnormalities and the deregulation of S100 gene
expression in various tumors. Up to date, many members of S100
family have been identified to be associated with tumor
development and metastasis [5,6]. However, the precise roles
and importance of S100 proteins in the development and
promotion of cancer are poorly understood. Understanding of
the biological function(s) of S100 proteins will depend on the
identification of S100 protein targets. Up to now, several possible
protein targets, including glyceraldehyde-3-phosphate dehydroge-
nase, annexin II, annexin VI, annexin XI, caldesmon and
CacyBP/SIP, have been shown to interact with S100 proteins in
vitro in a Ca
2+-dependent manner [5,7].
Calcyclin-binding protein (CacyBP/SIP), a 30 kDa protein
identified on the basis of its ability to interact with S100A6 in a
Ca
2+-dependent manner in Ehrlich ascites tumour (EAT) cells [8],
was previously thought as a multiple-drug resistance (MDR)-
related molecule in gastric cancer in our laboratory [9]. Through
use of a monoclonal antibody against CacyBP/SIP [10], we have
shown that overexpression of CacyBP/SIP inhibits the prolifera-
tion and tumorgenesis of renal cancer cells [11]. Further study has
suggested that CacyBP/SIP suppresses the growth of gastric
cancer [12]. Despite this progress, the effects of S100 proteins on
CacyBP/SIP in gastric cancer remain unclear. In addition,
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tion complex via binding Siah1 and Skp1 [13]. And this ligase was
described to regulate the degradation of non-phosphorylated b-
catenin [13].
CacyBP/SIP could bind S100, Siah1 and Skp1 by different
regions. The N-terminal region (aa 1–80) of CacyBP/SIP has been
shown to have affinity for Siah1. The C-terminal region of
CacyBP/SIP (aa178–229) is known to form a a-helix; this domain
may interact with S100 proteins, including S100A6 [14]. Skp1
binding domain does not overlap with the S100 binding region
and Skp1 binds to the middle part (aa78–155) of CacyBP/SIP
[15,16]. To observe the effects of S100 proteins on the biological
behavior of CacyBP/SIP in gastric cancer, eukaryotic expression
vectors for wild-type CacyBP/SIP and its truncated mutant
lacking the S100 protein binding domain (CacyBP/SIPDS100)
were successfully constructed and effectively expressed in MKN45
cells. An MTT assay, FACS assay, clonogenic assay and tumor
xenograft experiment were performed to evaluate the effects of
CacyBP/SIP on cell growth and tumorigenesis both in vitro and in
vivo. The results of these studies may contribute to the elucidation
of the effects of S100 proteins on the biological behavior of
CacyBP/SIP in gastric cancer cells.
Materials and Methods
Cell lines and animals
The gastric cancer cell line MKN45, which was found to be the
lowest expression of CacyBP/SIP in our previous study [12], was
preserved in our laboratory. The cells were cultivated in RPMI
1640 medium (GIBCO, Grand Island, NY, USA) supplemented
with 10% heat-inactivated fetal calf serum, penicillin (100 U/ml),
and streptomycin (100 mg/ml) in a CO2 incubator (Forma
Scientic, Marjetta, OH, USA). BALB/c nude mice at 4–6 weeks
of age were provided by the Shanghai Cancer Institute for the in
vivo tumorigenesis study. This study was performed in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Fourth Military Medical
University (Permit Number: 11016). All surgery was performed
under sodium pentobarbital anesthesia, and every effort was made
to minimize suffering.
Immunofluorescence staining
The cells were plated onto cleaned coverslips and fixed with
95% alcohol for 20 min at room temperature. The cells on the
coverslips were washed with PBS and permeablized for 10 min
with 0.5% Triton X-100 in PBS. The cells were incubated with
anti-S100A6 antibody (diluted 1:2000) after blocking with 3%
bovine serum albumin for 1 h. The cells were then incubated with
FITC-conjugated anti-mouse IgG (Santa Cruz Biotech., Santa
Cruz, USA) and mounted on glass slides with a mixture of glycerol
and polyvinyl alcohol containing DABCO (1,4- diazobicylo-
[2,2,2,]-octane). Immunofluorescence was analyzed with a
MRC-1024 Laser Scanning Confocal Imaging System (Bio-Rad).
Plasmid construction and cell transfection
Oligonucleotide primers containing the EcoRIo rEcoRV
restriction site were synthesized, respectively, for amplification of
the CDS sequence of CacyBP/SIP or a C-terminal deletion
(aa178–229) mutant of CacyBP/SIP (Accession AF_314752). The
two primers were: 59 gggaattcgaatatggcttcagaagagcta 39 (sense)
and 59 gcgatatctcaaaattccgtgtctcctttg 39 (anti-sense); 59 gggaattc-
gaatatggcttcagaagagcta 39 (sense) and 59 ccgatatcacacaatataa-
gaactgta 39 (anti-sense), respectively. The PCR conditions were:
5 min at 94u for initial denaturation, followed by 35 cycles of
45 sec at 94u, 45 sec at 60u, and 60 sec at 72u, with a final
extension of 10 min at 72u. The lengths of the PCR products were
687 bp for CDS, and 534 bp for C-terminal deletion. Each PCR
product was excised with EcoR I and EcoR V restriction digestion
and cloned into likewise digested pFLAG-CMV. The new vectors
were named pFLAG-CacyBP (wild-type) and pFLAG-DS100
(CacyBP/SIPDS100). The insert sequences were confirmed by
DNA sequencing.
Cell transfection was performed with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) as described by the manufacturer.
Briefly, cells were plated and grown to 70–90% confluence
without antibiotics. They were then transfected with 1 mg pFLAG-
CacyBP or pFLAG-DS100. At 24 h after transfection, G418
(350 mg/ml) was added to the culture media for the selection of
transfected cells. Mixed clones were expanded for an additional 6
weeks. Cells transfected with empty vector, pFLAG-CMV, were
used as a negative control. These stable cell lines were named
MKN45-CacyBP, MKN45-DS100 and MKN45-pFLAG for the
wild-type, truncated and negative control transfectants, respec-
tively.
Co-immunoprecipitation
The MKN45 transfectants were washed in PBS, harvested and
lysed on ice in a buffer containing 20 mM Tris-HCl (pH 7.5),
8m MM g C l 2, 150 mM NaCl, 0.2 mM EGTA, and 1% Nonidet
P-40. The extracts were centrifuged at 12,000 rpm for 25 min at
37u in a microcentrifuge. The supernatants were used for an
immunoprecipitation assay after the addition of protease
inhibitors (10 mg/L leupeptin, 5 mg/L aprotinin, 20 mg/L
soybean trypsin inhibitor, 1 mM phenylmethylsulfonyl fluoride)
and quantified by the Bradford method. The supernatants were
incubated with 30 ml protein A/G-Sepharose and 1 mg unrelated
antibody for 1–3 h at 37u (pre-clearance). The unbound fractions
were then incubated with serum containing antibodies against
CacyBP/SIP for 1.5 h at 4u. The mixture was then incubated
with additional protein A/G-Sepharose overnight at 4u. The
resin was then washed three times in a buffer containing 20 mM
Tris- HCl (pH 7.5) and 150 mM NaCl, twice in a buffer
containing 20 mM Tris-HCl (pH 7.5) and 500 mM NaCl, and
finally in 20 mM Tris-HCl at pH 7.5. All of the buffers that were
used were supplemented with protease inhibitors. The resin and
bound proteins were solubilized in an SDS sample buffer, boiled
for 5 min at 98u, and applied to an SDS polyacrylamide gel. The
expression of S100A6 was analyzed by western blotting with
antibody against S100A6.
Western blot
The cells were collected and lysed on ice in a buffer containing
[50 mmol/L Tris-Cl (pH 7.5), 150 mmol/L NaCl, 0.2 mmol/L
EDTA, 1 mmol/L PMSF and 1% NP 40], and then quantified by
the Bradford method. A measure of 100 mg of lysates was
electrophoresed in 10% SDS-PAGE and blotted on to a
nitrocellulose membrane. The membranes were blocked with
10% fat-free milk at room temperature for 2 h and incubated with
anti-CacyBP (1:1500) and anti-b-actin antibody (Sigma, 1:5000) at
4u overnight. After three washes for 15 min each in TBS
supplemented with 0.1% Tween 20 (TBST), the membrane was
incubated with peroxidase-conjugated goat anti-mouse/rabbit IgG
antibody (Amersham-Pharmacia Biotech, Beijing, China) for 2 h
at room temperature. Enhanced chemiluminescence (Amersham,
Freiburg, Germany) was used for detection.
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Cells were seeded onto a 96-well plate at 2.5610
3 cells/well in
RPMI 1640 media containing 10% heat-inactivated fetal calf
serum. Each sample had three replicates. The medium was
replaced at 2-day intervals, for 6 days. The cells were incubated
with 50 ml of 0.2% MTT for 4 h at 37u in a 5% CO2
atmosphere. Following MTT incubation, a 150 mla l i q u o to f
100% DMSO was added to each culture to dissolve the crystals.
Viable cells were counted every day by reading the absorbance at
490 nm using a 96-plate reader, BP800 (Dynex Technologies,
Chantilly, VA).
Cell cycle analysis
Subconfluent cells were washed with ice-cold PBS, suspended
in 0.5 ml ethanol and then kept at 4uC for 30 min. The
suspension was filtered through a 50-mm nylon mesh, and the
DNA content of stained nuclei was analyzed with a flow
cytometer (EPICS XL, Coulter, Miami, FL). The cell cycle
profile was analyzed using Multicycle-DNA Cell Cycle Analyzed
Software. The proliferative indices (PI) were calculated as follows:
PI=(G2+S)/(G1+S+G2).
Clonogenic assay
To measure the proliferation rate of a single cell in vitro, plate
clonogenic and soft agar clonogenic assays were performed [17].
For the plate clonogenic assay, 1610
3 cells were seeded into a 9-
cm dish and cultured in RPMI 1640 medium for two weeks to
allow for colony formation. The colonies were fixed in 70%
ethanol, stained with Giemsa solution and counted. For the soft
agar clonogenic assay, the cells were detached and plated in 0.3%
agarose with a 0.5% agarose underlay (1610
3/well in a 24-well
plate). The number of foci .100 mm was counted after 20 days.
Tumor growth in nude mice
Logarithmically growing cells (1610
7 cells) were trypsinized,
resuspended in 0.1 ml D’Hanks solution, and injected into the
neck hypodermia of each athymic nude mouse. The mice were
then monitored for tumor volume, overall health, and total body
weight. The size of the subcutaneous tumor mass was measured by
caliper for five weeks. Tumor volume was calculated according to
the formula: 0.56length6width
2. Each experimental group
consisted of five mice.
Reporter gene assay
To assay the effect of CacyBP/SIP and CacyBP/SIPDS100 on
the transcriptional activity of Tcf/LEF, the reporter gene assay
was performed as described [18]. Briefly, cells in a 24-well plate
(50,000 cells per well) were co-transfected with or without pFLAG-
CMV, pFLAG-CacyBP, pFLAG-DS100 and the reporter plasmid,
pTOPFLASH, containing wild-type Tcf/LEF binding sites using
Lipofectamine 2000; pRL-TK Renilla luciferase reporter served as
a control for transfection efficiency. The luciferase activity was
measured and quantitated in a luminometer using the Dual-
Luciferase Reporter Assay System (Promega, Southampton,
U.K.). Experiments were performed in triplicate and repeated
twice. Results are expressed as the mean of the ratio between the
firefly luciferase activity and the renilla luciferase activity.
Statistical analysis
All data were analyzed using the SPSS statistical software
package (SPSS, Inc., Chicago, Illinois), and P,0.05 was
considered statistically significant. The significance of the differ-
ence in frequency of CacyBP/SIP-positive staining between
adjacent tumor samples and tumors were analyzed by the chi-
square test. Student’s t test and one-way analysis of variance
followed by Dunnett’s multiple comparison tests were employed
for analysis of other data.
Results
Endogenous expression of S100A6 in gastric cancer cell
line MKN45
S100A6 was selected as a model to observe the effect of S100
proteins on the biological function of CacyBP/SIP. The
endogenous expression of S100A6 in gastric cancer cell line
MKN45 was first detected by western blot and immunofluores-
cence staining. As shown in Fig. 1A, S100A6 was expressed in
MKN45 cells. Immunofluorescence staining indicates that S100A6
was mainly distributed in the nuclear membrane with very little
found in the nuclear plasma of the MKN45 cells (Fig. 1B).
Interaction of S100A6 and CacyBP/SIP in gastric cancer
cells MKN45
In a previous report, CacyBP/SIP, which was expressed at a
relatively low level in MKN45 cells, was widely expressed in
several different types of gastric cancer cell lines [12]. In order to
evaluate the interaction between S100A6 and CacyBP/SIP, wild-
type and mutant (aa178–229) CacyBP/SIP cDNAs were cloned
into the pFLAG-CMV vector and stably transfected into MKN45
cells. We assessed the expression of CacyBP/SIP in these stable
cell lines by western blot. As shown in Fig. 2A, FLAG-tagged
CacyBP/SIP was detected in the wild-type and mutant CacyBP/
SIP transfectants with anti-Flag antibody, while no signal was
found in cells transfected with empty vector.
The interaction between S100A6 and CacyBP/SIP in transfec-
tant MKN45 cells was then evaluated by co-immunoprecipitation.
After incubation with anti-CacyBP antibody, immunoprecipitate
were detected by S100A6 antibody. As shown in Fig. 2B, an
interaction between S100A6 and wild-type CacyBP/SIP was
observed in MKN45-CacyBP cell lysates; however, mutant
CacyBP/SIP that was truncated from the aa178–229 region,
produced little signal in the co-immunoprecipitation assay.
Therefore, the truncated mutant CacyBP/SIP was named
CacyBP/SIPDS100 and provides a useful tool for investigation
of the effects of S100A6 on the biological behavior of CacyBP/SIP
in gastric cancer cells.
Effects of S100A6 on cell proliferation induced by
CacyBP/SIP in the gastric cancer cell line MKN45 in vitro
MTT and FACS assays were performed to examine the effects
of S100A6 on cell proliferation induced by CacyBP/SIP in
MKN45 cells in vitro. Compared with the empty vector
transfectants, MKN45-pFLAG, both wild-type and CacyBP/
SIPDS100 transfectants showed significantly decreased rates of
cell proliferation by the MTT assay (P,0.05) (Fig. 3A). However,
CacyBP/SIPDS100 transfectants exhibited a significantly more
decreased growth rate compared with wild-type CacyBP/SIP
transfectants (P,0.05).
The results of the cell cycle analysis by FACS similarly indicate
that overexpression of either wild or mutant CacyBP/SIP reduces
MKN45 proliferation. However, the average proliferative indexes
(PI) of MKN45-DS100 cells (0.1960.03) was lower than that of
MKN45-CacyBP cells (0.2960.02) (P,0.05) (Fig. 3B). Taken
together, these data strongly indicate that wild-type CacyBP/SIP
inhibits the proliferation of MKN45 cells, while CacyBP/
SIPDS100 intensifies this inhibition of proliferation.
S100A6 Negatively Regulates CacyBP/SIP
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30185Effects of S100A6 on tumorigenesis induced by CacyBP/
SIP in the MKN45 gastric cancer cell line in vitro and in
vivo
Anchorage-independent growth is an important characteristic of
in vitro tumor growth. Therefore, we examined whether upregula-
tion of CacyBP/SIP expression inhibited MKN45 cell growth in
media and soft agar. As shown in Fig. 4A and B, CacyBP/SIP
expression resulted in a marked reduction of MKN45 cell growth
in a colony formation assay, with an average reduction of 32.1% in
medium and 62.0% in soft agar (P,0.05). However, transfection
of CacyBP/SIPDS100 resulted in an even greater decrease in
growth with an average decrease in rates of 84.2% in medium and
82.8% in soft agar (P,0.01).
To confirm this effect in vivo, we subcutaneously injected
MKN45-CacyBP, MKN45-DS100 and MKN45-pFLAG cells in
to the neck hypodermia of nude mice. After three weeks, the
average tumor volume in each group was significantly different
from that of the others. At the 5
th week, the average tumor volume
in the MKN45-pFLAG group was 776.9690.9 mm
3, which is
significantly more than that of the MKN45-CacyBP group
(578.9651.2 mm
3)( P,0.05), and even more than that of the
MKN45-DS100 group (364.9671.9 mm
3)( P,0.05) (Fig. 4C).
Effects of S100A6 on CayBP/SIP-mediated b –catenin
degradation
As a component of ubiquitin ligase complex, CacyBP/SIP is
involved in the degradation of unphosphorylated b –catenin via
binding Skp1 and Siah1. So expression of b –catenin was detected
to indirectly evaluate the influence of S100 on Siah1-CacyBP/SIP-
Skp1 unbiquitin ligase. Firstly, co-immunoprecipitation assay
showed that truncated mutant CacyBP/SIP bind both Skp1 and
Siah1 (Fig. 5A), suggesting S100A6 did not affect the formation of
Siah1-CacyBP/SIP-Skp1 unbiquitin ligase complex. Secondly, b–
catenin protein in MKN45-DS100 cells is significantly decreased,
compared to MKN45-CacyBP cells, while with no change
occurred in the mRNA (Fig. 5B). In addition, because b-catenin
is required as a cofactor for the activation of the transcription
factor, Tcf/LEF, we determined the effects of CayBP/SIPDS100
on Tcf/LEF activity using transient transfection reporter gene
assays. Expression of CacyBP/SIPDS100 resulted in lower Tcf/
LEF activity than wild-type CacyBP/SIP (Fig. 5C). MG132,
inhibitor of proteasome, could eliminate the effect of both wild-
type CacyBP/SIP and CacyBP/SIPDS100 on Tcf/LEF activity.
Taken together, we inferred that S100A6 might affect CayBP/SIP
mediated b –catenin degradation via interacting with CayBP/SIP.
Discussion
S100 family proteins have gained interest because of their
differential expression in tumor tissues and their involvement in
cancer progression and metastasis [19–22]. S100 proteins interact
with some target proteins in calcium-dependent or calcium-
independent manner and further regulate function of these targets
[5,23]. CacyBP/SIP is a new target protein that can interact with
S100 proteins, including S100A6, S100A1, S100B, and S100P,
but not to S100A4, calbindin D, parvalbumin or calmodulin
[8,16]. Previous works in our lab showed that overexpression of
CacyBP/SIP could inhibit the proliferation and tumorigenesis of
gastric cancer and renal cell carcinoma [11,12]. Despite this
progress, the effects of S100 proteins on CacyBP/SIP remain to be
investigated.
Figure 1. Endogenous expression of S100A6 in the MKN45 gastric cancer cell line. (A) Endogenous expression of S100A6 in MKN45 gastric
cancer cells was detected by western blot. (B) Immunofluorescent staining of S100A6 in MKN45 cells. (a) Immunofluorescent staining of S100A6 with
anti-S100A6 antibody (in green); (b) Detection of nuclei with propidium iodide (in red); (c) Merged picture.
doi:10.1371/journal.pone.0030185.g001
Figure 2. Interaction of S100A6 and CacyBP/SIP in the MKN45
gastric cancer cell line. (A) Western blot analysis of the transfectants
CacyBP/SIP and CacyBP/SIPDS100 transfectants with anti-FLAG and
anti-CacyBP antibodies. b-actin was used as a loading control. (B) Co-
immunoprecipitation assay to detect an interaction between S100A6
and CacyBP/SIP in MKN45 cells. After incubation with anti-CabyBP
antibody, the binding sites were detected by anti-S100A6 antibody.
doi:10.1371/journal.pone.0030185.g002
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function, we constructed the truncated CacyBP/SIP mutant
without S100 protein binding domain, so that mutant protein
could not interact S100 proteins and retains ability to interact with
Siah1 and Skp1. In this study, eukaryotic expression vectors for
wild-type CacyBP/SIP and its truncated mutant were effectively
expressed in MKN45 cells. Co-immunoprecipitation demonstrat-
ed an interaction between S100A6 and wild-type CacyBP/SIP in
MKN45 cells. However, CacyBP/SIPDS100 showed little signal
by the co-immunoprecipitation assay, indicating a weak or no
interaction with S100A6. MTT assay, FACS assay, clonogenic
assay and tumor xenograft experiment in nude mice were
performed to test the effect of wild and mutant CacyBP/SIP on
cell growth and tumorigenesis both in vitro and in vitro. These
experiments showed that overexpression of CacyBP/SIP could
inhibit the proliferation and tumorigenesis of MKN45 gastric
cancer cells. Importantly, cells transfected with CacyBP/
SIPDS100 exhibited more intense effects relative to wild-type
transfectants, suggesting that S100 proteins might negatively
regulate the inhibition of cell proliferation induced by CacyBP/
SIP in gastric cancer cells.
The mechanism employed by S100A6 to modulate CacyBP/
SIP function might lie in protein interactions and functions.
CacyBP/SIP is identified to be involved in ubiquitination and
degradation of b-catenin [24–28]. b- catenin was found to be
overexpressed or activated in proliferating cells and in many
tumors [29–31]. Fukushima et al. [32] found that CacyBP/SIP
knockout cells show impaired (-catenin degradation and a
defective G1 cell cycle checkpoint, indicating that the b-catenin
degradation pathway mediated by CacyBP/SIP defines an
essential checkpoint for thymocyte development and cell cycle
progression. Our previous studies also showed that CacyBP/SIP
Figure 3. Effects of CacyBP/SIP on cell proliferation in vitro. (A) Detection of the cell growth rate in vitro. Cell number was evaluated by
absorbance at 490 nm using the MTT assay at the indicated times. The value shown is the mean of three determinations. (B) Cell cycle distribution
and proliferative indices (PI) of the transfected cells. The cells were detergent extracted, stained with propidium iodide, and analyzed by flow
cytometry. PI=(G2+S)/(G1+S+G2).
doi:10.1371/journal.pone.0030185.g003
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degradation of b –catenin. Whether S100 regulates CacyBP/SIP-
mediated ubiquitin ligase retains unknown. Accumulating evi-
dences showed that several members of the S100 protein family
could regulate the activation of their target proteins [33,34]. A
recently discovered yeast homolog of CacyBP/SIP, Sgt1, not only
interacts with S100 proteins in calcium regulated-manner, but also
associates with Skp1 to form Skp1/cullin1/F- box ubiquitin ligase
complex [35]. It has been found that S100A6 could inhibit the
phosphorylation of Sgt1 by casein kinase II to affect the activity
[36]. In our present experiment, we also identified that CacyBP/
SIPDS100 retain ability to associate with Skp1 and Siah1,
suggesting S100 molecule might not affect formation of Siah1/
Skp1/CacyBP ubiquitin ligase complex. Nevertheless, b–catenin
protein without a change of the mRNA level in CacyBP/
SIPDS100 transfected cells is markedly lower than wild-type
transfectant cells. The transcriptional activity of Tcf/LEF, a target
gene of b–catenin, was decreased in conjunction with mutant
CacyBP/SIP without S100 binding, compared to wild CacyBP/
SIP. Accoding to these results, we postulate that S100 protein
might negatively regulate the activity of Siah1-CacyBP/SIP-Skp1
ubiquitin ligase by interaction with CacyBP/SIP. So blocking the
combination of S100 and CacyBP/SIP could promote b –catenin
degradation, result in inhibiting the proliferation of cancer cells.
This speculation can be partially supported by Lee et al that in
cells with diminished level of S100A6 the amount of b –catenin is
reduced [26]. The results are in agreement with data regarding the
up-regulation of S100 proteins and deficient degradation of b –
catenin in tumor and proliferating cells [37]. In addition, CacyBP/
SIP was shown to interact with tubulin and ERK1/2 and play
important role in rearrangements of the cytoskeleton, cell
differentiation or degeneration [38–42].
Figure 4. Effects of CacyBP/SIP transfectants on tumorigenesis. (A) Detection of the clonogenic formation in medium. (B) Detection of the
clonogenic formation in soft agar. Cells were placed in media containing soft agar or on a plate and incubated for 20 days. The number of foci
.100 mm was counted. Vertical bars represent the mean 6 SD from at least three separate experiments, each conducted in triplicate. (C) In vivo
tumorigenicity was evaluated by a nude mice assay. Mice were injected subcutaneously with 1610
7 transfected cells. The volume of each tumor was
calculated according to the formula 0.56length6width
2. Two independent experiments were performed and each experimental group consisted of
five mice.
* P,0.05 vs. MKN45-pFLAG,
** P,0.01 vs. MKN45-pFLAG,
# P,0.05 vs. MKN45-CacyBP.
doi:10.1371/journal.pone.0030185.g004
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S100A6 protein negatively regulates CacyBP/SIP-mediated
inhibition of gastric cancer cell proliferation, partly through effect
on b-catenin degradation and transcriptional activation of Tcf/
LEF. However, the underlying mechanisms for regulation of
S100A6 on protein ubiquitination and other functions via
CacyBP/SIP-dependent pathway require further investigation.
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